» Articles » PMID: 686708

Pharmacokinetics of Netilmicin in the Presence of Normal or Impaired Renal Function

Overview
Specialty Pharmacology
Date 1978 Jul 1
PMID 686708
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A pharmacokinetic study of netilmicin was conducted in 12 healthy subjects and 24 subjects with chronic renal failure. After intramuscular administrations of 2 and 3 mg of netilmicin per kg in normal subjects, the mean peak serum concentrations were 5.46 and 8.83 mug/ml, respectively. After intravenous infusions of identical doses, the mean maximum serum levels, occurring at the end of the infusion, were 11.79 and 15.75 mug/ml, respectively. The pharmacokinetic data were very similar via the two routes of administration and for the two doses. The elimination half-life was 2.20 h, and 80 to 90% of the injected dose was recovered in urine during the first 24 h. After intramuscular administration of 2 mg/kg in subjects with chronic renal impairment, the elimination half-life increased to 29.48 h, and urinary elimination was inversely related to the degree of impairment. A study was conducted throughout hemodialysis sessions: serum concentrations decreased by 63.3%. The linear relationships between the elimination rate constant and creatinine clearance and the elimination half-life and serum creatinine allowed us to establish dosage schedules according to the degree of renal failure.

Citing Articles

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen M, Zavascki A, Tsai H, Tao X Antimicrob Agents Chemother. 2019; 63(7).

PMID: 30988147 PMC: 6591590. DOI: 10.1128/AAC.00425-19.


Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Yeh E, Brown G Can J Hosp Pharm. 2012; 62(6):457-63.

PMID: 22478933 PMC: 2827012. DOI: 10.4212/cjhp.v62i6.843.


Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Jauregizar N, Wald J, Astobieta A, Rodriguez Sasiain J, Lukas J, Calvo R Br J Clin Pharmacol. 2003; 55(6):552-9.

PMID: 12814449 PMC: 1884271. DOI: 10.1046/j.1365-2125.2003.01783.x.


Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration.

Lin C, Korduba C, Affrime M, Radwanski E, Nomeir A, Batra V Antimicrob Agents Chemother. 1995; 39(10):2201-3.

PMID: 8619567 PMC: 162914. DOI: 10.1128/AAC.39.10.2201.


Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.

Keller F, Erdmann K, Giehl M, Buettner P Clin Pharmacokinet. 1993; 25(1):71-9.

PMID: 8354018 DOI: 10.2165/00003088-199325010-00005.


References
1.
CHABBERT Y, BOULINGRE H . [Practical modifications concerning the determination of antibiotics in clinical practice]. Rev Fr Etud Clin Biol. 1957; 2(6):636-40. View

2.
Yap B, Stewart D, Bodey G . Clinical pharmacology of netilmicin. Antimicrob Agents Chemother. 1977; 12(6):717-20. PMC: 430010. DOI: 10.1128/AAC.12.6.717. View

3.
Meyers B, Hirschman S, Wormser G, Siegel D . Pharmacokinetic study of netilmicin. Antimicrob Agents Chemother. 1977; 12(1):122-3. PMC: 352165. DOI: 10.1128/AAC.12.1.122. View

4.
RIFF L, Moreschi G . Netilmicin and gentamicin: comparative pharmacology in humans. Antimicrob Agents Chemother. 1977; 11(4):609-14. PMC: 352037. DOI: 10.1128/AAC.11.4.609. View

5.
KABINS S, Nathan C, Cohen S . In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Antimicrob Agents Chemother. 1976; 10(1):139-45. PMC: 429703. DOI: 10.1128/AAC.10.1.139. View